Urinary Bladder, OveractivePhase 4SAFINANCT00806494
UK Study Assessing Flexible Dose Fesoterodine in Adults
A Phase 4 study testing Fesoterodine in people with Urinary Bladder, Overactive, run by Pfizer at 39 sites in United Kingdom.
Trial summary
To explore the effects of fesoterodine when used in a flexible dose manner Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Urinary Bladder, Overactive
- What is being tested?
- Fesoterodine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 331 participants
- Where
- 39 sitesUnited Kingdom
- Study dates
- Feb 2009to Jan 2010
- Phase
- Phase 4
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female >18 years old
- OAB for >3 months
Who cannot join
- Patients with conditions that would contraindicate for fesoterodine use
- Patients with significant hepatic and renal disease or other significant unstable diseases.
- OAB symptoms caused by neurological conditions, known pathologies of urinary tract, etc.
Trial locations and contacts
39 sites in 1 country.
39 sites in 1 country
United Kingdom39 sites
Pfizer Investigational Site
Addlestone, Surrey, KT15 2BH
Pfizer Investigational Site
Ashford, Middlesex, TW15 3EA
Pfizer Investigational Site
Ayrshire, Scotland, KA12 0AY
Pfizer Investigational Site
Baillieston, Glasgow, G69 7AD
Pfizer Investigational Site
Bath, Somerset, BA1 2SR
Pfizer Investigational Site
Bath, BA2 3HT
Pfizer Investigational Site
Bath, BA2 4BY
Pfizer Investigational Site
Bexhill-on-Sea, East Sussex, TN40 1JJ
Pfizer Investigational Site
Blackpool, Lancashire, FY3 7EN
Pfizer Investigational Site
Blackpool, Lancashire, FY4 3AD
Pfizer Investigational Site
Bradford on Avon, Wiltshire, BA1 5DQ
Pfizer Investigational Site
Bristol, BS2 8HW
Pfizer Investigational Site
Bucks, HP22 5LB
Pfizer Investigational Site
Chesterfield, Derbyshire, S40 4TF
Pfizer Investigational Site
Chesterfield, Derbyshire, S44 5BL
Pfizer Investigational Site
Chippenham, Wilts, SN14 8GT
Pfizer Investigational Site
Crewe, Cheshire, CW1 4QJ
Pfizer Investigational Site
Doncaster, South Yorkshire, DN9 1ND
Pfizer Investigational Site
Ely, Cambridgeshire, CB7 5JD
Pfizer Investigational Site
Falkirk, Scotland, FK1 5QE
Pfizer Investigational Site
Fowey, Cornwall, PL23 1DT
Pfizer Investigational Site
Glasgow, G51 4TF
Pfizer Investigational Site
Hertfordshire, WD25 0EA
Pfizer Investigational Site
Hinckley, Leicestershire, LE10 2SE
Pfizer Investigational Site
Leatherhead, Surrey, KT24 6QT
Pfizer Investigational Site
London, SE5 9RS
Pfizer Investigational Site
London, W1P 9LL
Pfizer Investigational Site
Mortimer, Reading, RG7 2BH
Pfizer Investigational Site
Northants, NN8 4RW
Pfizer Investigational Site
Northwood, Middlesex, HA6 2RN
Pfizer Investigational Site
Penzance, Cornwall, TR18 4JH
Pfizer Investigational Site
Plymouth, Devon, PL5 3JB
Pfizer Investigational Site
Plymouth, PL6 8DH
Pfizer Investigational Site
Sheffield, South Yorkshire, S7 2DW
Pfizer Investigational Site
Swansea, SA6 6NL
Pfizer Investigational Site
Swindon, SN25 4YZ
Pfizer Investigational Site
West Didsbury, Manchester, M20 2LR
Pfizer Investigational Site
Winterton, Scunthorpe, DN15 9TA
Pfizer Investigational Site
Worthing, West Sussex, BN11 2DH
About this study
Official title: A 12 Week, Multi-centre, Open Label Study To Evaluate The Efficacy, Tolerability And Safety Of A Fesoterodine Flexible Dose Regimen In Patients With Overactive Bladder.
To explore the effects of fesoterodine when used in a flexible dose manner
- Conditions
- Urinary Bladder, Overactive
- Being tested
- Fesoterodine
- Keywords
- Fesoterodine, Open Label, Flexible Dose, OAB
- Medical subject headings
- Urinary Bladder, Overactive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FesoterodineDrug
Fesoterodine 4mg for 4 weeks, escalating to fesoterodine 8mg if tolerated
| Study group | Role | What they receive |
|---|---|---|
| Treatment Arm | Experimental | Fesoterodine 4mg, escalating to 8mg as required Receives: Drug: Fesoterodine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 12
The number of micturitions was measured by the 3-day bladder diary completed for the 3 consecutive days preceding each clinic visit. The mean number of micturitions per 24 hours was calculated as the sum of all micturitions recorded in the diary divided by the number of days the diary was completed at that visit. Change=mean at observation minus mean at baseline. Negative change, more specifically (ie), a decrease in number of micturitions relative to baseline=improvement.
Measured: Baseline, Week 12
Secondary outcomes (20)
Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 4
The number of micturitions was measured by the 3-day bladder diary completed for the 3 consecutive days preceding each clinic visit. The mean number of micturitions per 24 hours was calculated as the sum of all micturitions recorded in the diary divided by the number of days the diary was completed at that visit. Change=mean at observation minus mean at baseline. Negative change, ie, decrease in number of micturitions relative to baseline=improvement.
Measured: Baseline, Week 4
Percentage Change From Baseline in the Number of Micturitions Per 24 Hours at Weeks 4 and 12
Percentage change from baseline in micturitions was calculated as change in mean number of micturitions per 24 hours at that visit divided by the baseline mean number of micturitions per 24 hours, multiplied by 100.
Measured: Baseline, Week 4 and Week 12
Change From Baseline in Mean Number of Nocturnal Micturitions Per 24 Hours at Weeks 4 and 12
Nocturnal micturitions were defined as those occurring between the time the subject went to bed and the time he or she arose to start the next day. The mean number of nocturnal micturitions per 24 hours was calculated as the total number of nocturnal micturitions divided by the total number of diary days collected at that visit. Change=mean at observation minus mean at baseline. Negative change, ie, decrease in number of nocturnal micturitions relative to baseline=improvement.
Measured: Baseline, Week 4 and Week 12
Percentage Change From Baseline in Nocturnal Micturitions Per 24 Hours at Weeks 4 and 12
Percentage change from baseline in nocturnal micturitions was calculated as change in mean number of nocturnal micturitions per 24 hours at that visit divided by the baseline mean number of nocturnal micturitions per 24 hours, multiplied by 100.
Measured: Baseline, Week 4 and Week 12
Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Weeks 4 and 12
UUI episodes were defined as those with a Urinary Sensation Scale (USS) rating of 5 in the diary. USS: 5-item scale to measure urinary urgency; range: 1 (no feeling of urgency) to 5 (unable to hold; leak urine).
Mean number of UUI episodes per 24 hours was calculated as total number of micturitions with USS rating of 5 divided by total number of diary days collected at that visit. Change=mean at observation minus mean at baseline. Negative change, ie, decrease in number of UUI episodes relative to baseline=improvement.
Measured: Baseline, Week 4 and Week 12
Percentage Change From Baseline in UUI Episodes Per 24 Hours at Weeks 4 and 12
Percentage change from baseline in UUI episodes was calculated as change in mean number of UUI episodes per 24 hours at that visit divided by the baseline mean number of episodes per 24 hours, multiplied by 100.
Measured: Baseline, Week 4 and Week 12
Change From Baseline in Mean Number of Urgency Episodes Per 24 Hours at Weeks 4 and 12
Urgency episodes were defined as those with a USS rating of >=3 in the diary. USS: 5-item scale to measure urinary urgency; range: 1 (no feeling of urgency) to 5 (unable to hold; leak urine). Mean number of urgency episodes per 24 hours was calculated as total number of urgency episodes divided by total number of diary days collected at that visit. Change=mean at observation minus mean at baseline. Negative change, ie, decrease in number of urgency episodes relative to baseline=improvement.
Measured: Baseline, Week 4 and Week 12
Percentage Change From Baseline in Urgency Episodes Per 24 Hours at Weeks 4 and 12
Percentage change from baseline in urgency episodes was calculated as change in mean number of urgency episodes per 24 hours at that visit divided by the baseline mean number of urgency episodes per 24 hours, multiplied by 100.
Measured: Baseline, Week 4 and Week 12
Change From Baseline in Mean Number of Nocturnal Urgency Episodes (NUEs) Per 24 Hours at Weeks 4 and 12
NUEs were defined as those with a USS rating of >=3 in the diary, occurring between the time the participant goes to bed and the time he/she arises to start the next day. USS: 5-item scale to measure urinary urgency; range: 1 (no feeling of urgency) to 5 (unable to hold; leak urine).
Mean number of NUEs per 24 hours was calculated as total number of NUEs divided by total number of diary days collected at that visit. Change=mean at observation minus mean at baseline. Negative change, ie, decrease in number of NUEs relative to baseline=improvement.
Measured: Baseline, Week 4 and Week 12
Percentage Change From Baseline in NUEs Per 24 Hours at Weeks 4 and 12
Percentage change from baseline in NUEs was calculated as change in mean number of NUEs per 24 hours at that visit divided by the baseline mean number of NUEs per 24 hours, multiplied by 100.
Measured: Baseline, Week 4 and Week 12
Change From Baseline in Mean Number of Severe Urgency Episodes (SUEs) Per 24 Hours at Weeks 4 and 12
SUEs were defined as those with a USS rating of >=4 in the diary. USS: 5-item scale to measure urinary urgency; range: 1 (no feeling of urgency) to 5 (unable to hold; leak urine). Mean number of SUEs per 24 hours was calculated as total number of SUEs divided by total number of diary days collected at that visit. Change=mean at observation minus mean at baseline. Negative change, ie, decrease in number of SUEs relative to baseline=improvement.
Measured: Baseline, Week 4 and Week 12
Percentage Change From Baseline in SUEs Per 24 Hours at Weeks 4 and 12
Percentage change from baseline in SUEs was calculated as the change in mean number of SUEs per 24 hours at that visit divided by the baseline mean number of SUEs per 24 hours, multiplied by 100.
Measured: Baseline, Week 4 and Week 12
Change From Baseline in Mean Number of Incontinence Pads Used Per 24 Hours at Weeks 4 and 12
The mean number of incontinence pads used per 24 hours was calculated as the total number of incontinence pads used divided by the total number of diary days collected at that visit. Change=mean at observation minus mean at baseline. Negative change, ie, decrease in number of incontinence pads used relative to baseline=improvement.
Measured: Baseline, Week 4 and Week 12
Change From Baseline in Patient Perception of Bladder Condition (PPBC) at Weeks 4 and 12
PPBC: self-administered, single-item, questionnaire to describe perception of participants bladder-related problems (rated on 6-point scale: 1=no problems at all, 2=some very minor, 3=some minor, 4=some moderate, 5=severe, 6=many severe problems). Score change=score at observation minus score at baseline; re-scaled to 4-point categorical variables (major improvement [score difference <=-2]; minor improvement [score difference =-1]; no change [score difference = 0]; deterioration [score difference >=1]), based on PPBC score.
Measured: Baseline, Week 4 and Week 12
Change From Baseline in Urgency Perception Scale (UPS) at Weeks 4 and 12
UPS: self-administered, single-item questionnaire to measure participant's perception of urinary urgency (rated on 3-point scale: 1=usually not able to hold urine; 3=usually able to finish what I am doing before going to toilet without leaking). Score change=score at observation minus score at baseline; re-scaled to 3-point categorical variables (improvement [Increase of 1 or more points in difference of scores]; no change [score difference=0]; deterioration [Negative difference of scores], based on UPS score, with number of participants in each of the 3-point categories.
Measured: Baseline, Week 4 and Week 12
Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score at Weeks 4 and 12
OAB-q symptom bother scale (8 items) is part of the OAB-q. Symptom bother score=sum of scores for items 1 to 8 (each symptom bother item measured on 6-point Likert scale ranging from 1 (not at all) to 6 (a very great deal). Lowest possible raw score=8; highest possible score=48. Data analyzed based on transformation of score to a 0 to 100 scale: (Actual total raw score - lowest possible value of raw score)/raw score range * 100. 0=no symptom bother, 100=high symptom bother. Change=mean score at observation minus mean score at baseline, negative change in score=improvement.
Measured: Baseline, Week 4 and Week 12
Change From Baseline in the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) Score at Week 12
ICIQ-SF: self-administered questionnaire for assessment and quantification of incontinence and its impact on quality of life. ICIQ score=sum of the responses to 3 questions: How often do you leak urine? (range: 0=never to 5=all the time); How much urine do you usually leak? (range: 0=none to 6=a large amount); Overall, how much does leaking urine interfere with your everyday life? (range: 0=not at all to 10=a great deal). Score range=0 (low bother from urine leakage) to 21 (maximum bother). Negative change (decrease) from baseline in score value=reduced level of bother.
Measured: Baseline, Week 12
Number of Participants With Each Categorical Response at Week 12 for Benefit, Satisfaction and Willingness to Continue (BSW) Questionnaire
BSW: 3-item questionnaire to assess participants perception of effect of treatment in terms of treatment benefit, satisfaction with treatment, and participants willingness to continue treatment. Response to each item recorded in dichotomous fashion (Benefit: yes/no, yes - little benefit/much benefit; Satisfaction: yes/no, yes - a little satisfied/very satisfied, no - a little dissatisfied/very dissatisfied; Willingness to continue: yes/no, yes - a little bit willing/very willing, no - a little unwilling/very unwilling).
Measured: Week 12 (or Early Withdrawal)
Percentage of Participants Reporting Satisfaction on the Treatment Satisfaction Questionnaire (TSQ) at Week 12
TSQ: Independent component of the overactive bladder TSQ. Self- administered, 1-item measure of participant satisfaction for participants receiving treatment for OAB. The 5 categorical responses were grouped to 'Satisfied' (including 'very satisfied' and 'somewhat satisfied') and 'Dissatisfied' (including 'very dissatisfied','somewhat dissatisfied', and 'neither dissatisfied nor satisfied'). Percentage of participants reporting satisfaction included those with categorical responses of 'very satisfied' and 'somewhat satisfied'.
Measured: Week 12 (or Early Withdrawal)
Change From Baseline in King's Health Questionnaire (KHQ) Domain Scores at Week 12
KHQ: Self-administered questionnaire containing 21 questions scored in 9 domains (general health perception, incontinence impact, role limitations, physical limitations, social limitations, personal relationships, emotions, sleep/energy, severity of urinary symptoms). Each domain was a categorical scale that was converted to a numeric score. All domains transformed to a range of 0 to 100, where 0=best outcome/response and 100=worst outcome/response. Change=mean score at Week 12 minus mean score at baseline, negative change from baseline=improvement.
Measured: Baseline, Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Dec 2008 (estimated)
- Study startFeb 2009
- Primary completionJan 2010
- Study completionJan 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Urinary Bladder, OveractiveStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 331 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00806494
- Sponsor's protocol ID
- A0221058
- Acronym
- SAFINA
- Status last verified
- Jan 2011
- First submitted
- 9 Dec 2008
- Last updated
- 26 Jan 2011
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Jan 2011. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A 12 Week, Multi-centre, Open Label Study To Evaluate The Efficacy, Tolerability And Safety Of A Fesoterodine Flexible Dose Regimen In Patients With Overactive Bladder.
- ClinicalTrials.gov ID
- NCT00806494
- Acronym / sponsor ID
- SAFINA / A0221058
- Conditions
- Urinary Bladder, Overactive
- Keywords
- Fesoterodine, Open Label, Flexible Dose, OAB
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 331 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- Feb 2009
- Primary completion
- Jan 2010 (actual)
- Study completion
- Jan 2010 (actual)
- First posted
- 10 Dec 2008 (estimated)
- Results
- Posted 26 Jan 2011
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To explore the effects of fesoterodine when used in a flexible dose manner
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Treatment Arm | Experimental | Drug: FesoterodineFesoterodine 4mg, escalating to 8mg as required |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Male or female >18 years old
- OAB for >3 months
Key exclusion criteria (3 listed)
- Patients with conditions that would contraindicate for fesoterodine use
- Patients with significant hepatic and renal disease or other significant unstable diseases.
- OAB symptoms caused by neurological conditions, known pathologies of urinary tract, etc.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FesoterodineFesoterodine 4mg for 4 weeks, escalating to fesoterodine 8mg if tolerated | Drug | Treatment Arm |
Primary outcome
Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 12
Time frame: Baseline, Week 12
The number of micturitions was measured by the 3-day bladder diary completed for the 3 consecutive days preceding each clinic visit. The mean number of micturitions per 24 hours was calculated as the sum of all micturitions recorded in the diary divided by the number of days the diary was completed at that visit. Change=mean at observation minus mean at baseline. Negative change, more specifically (ie), a decrease in number of micturitions relative to baseline=improvement.
20 secondary outcomes
Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 4
Time frame: Baseline, Week 4
Percentage Change From Baseline in the Number of Micturitions Per 24 Hours at Weeks 4 and 12
Time frame: Baseline, Week 4 and Week 12
Change From Baseline in Mean Number of Nocturnal Micturitions Per 24 Hours at Weeks 4 and 12
Time frame: Baseline, Week 4 and Week 12
Percentage Change From Baseline in Nocturnal Micturitions Per 24 Hours at Weeks 4 and 12
Time frame: Baseline, Week 4 and Week 12
Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Weeks 4 and 12
Time frame: Baseline, Week 4 and Week 12
Percentage Change From Baseline in UUI Episodes Per 24 Hours at Weeks 4 and 12
Time frame: Baseline, Week 4 and Week 12
Change From Baseline in Mean Number of Urgency Episodes Per 24 Hours at Weeks 4 and 12
Time frame: Baseline, Week 4 and Week 12
Percentage Change From Baseline in Urgency Episodes Per 24 Hours at Weeks 4 and 12
Time frame: Baseline, Week 4 and Week 12
Change From Baseline in Mean Number of Nocturnal Urgency Episodes (NUEs) Per 24 Hours at Weeks 4 and 12
Time frame: Baseline, Week 4 and Week 12
Percentage Change From Baseline in NUEs Per 24 Hours at Weeks 4 and 12
Time frame: Baseline, Week 4 and Week 12
Change From Baseline in Mean Number of Severe Urgency Episodes (SUEs) Per 24 Hours at Weeks 4 and 12
Time frame: Baseline, Week 4 and Week 12
Percentage Change From Baseline in SUEs Per 24 Hours at Weeks 4 and 12
Time frame: Baseline, Week 4 and Week 12
Change From Baseline in Mean Number of Incontinence Pads Used Per 24 Hours at Weeks 4 and 12
Time frame: Baseline, Week 4 and Week 12
Change From Baseline in Patient Perception of Bladder Condition (PPBC) at Weeks 4 and 12
Time frame: Baseline, Week 4 and Week 12
Change From Baseline in Urgency Perception Scale (UPS) at Weeks 4 and 12
Time frame: Baseline, Week 4 and Week 12
Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score at Weeks 4 and 12
Time frame: Baseline, Week 4 and Week 12
Change From Baseline in the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) Score at Week 12
Time frame: Baseline, Week 12
Number of Participants With Each Categorical Response at Week 12 for Benefit, Satisfaction and Willingness to Continue (BSW) Questionnaire
Time frame: Week 12 (or Early Withdrawal)
Percentage of Participants Reporting Satisfaction on the Treatment Satisfaction Questionnaire (TSQ) at Week 12
Time frame: Week 12 (or Early Withdrawal)
Change From Baseline in King's Health Questionnaire (KHQ) Domain Scores at Week 12
Time frame: Baseline, Week 12
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jan 2011.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
Related trials for Urinary Bladder, Overactive
Recruiting
Safety and Performance of UCon Patch Electrode
Urinary Incontinence, Urinary Incontinence, Urge
Active, not recruitingPhase 2/3
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
Urinary Incontinence, Overactive Bladder Syndrome
Recruiting
UCon Treatment of Overactive Bladder (OAB) in Males
Urinary Incontinence, Urge Incontinence
Active, not recruitingObservational study
Overactive Bladder Symptoms and Urinary Incontinence In Women With Rheumatoid Arthritis
Rheumatoid Arthritis, Rheumatoid Arthritis (RA)
RecruitingObservational study
Predictive Value of Inflammatory Biomarkers for Mirabegron Response in Women With Overactive Bladder
Overactive Bladder (OAB)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
39 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Fesoterodine in people with Urinary Bladder, Overactive, run by Pfizer at 39 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Jan 2011. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 39 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 26 Jan 2011). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 12 (time frame: Baseline, Week 12). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jan 2011.